Oragenics Inc (OGEN) Licenses Weight-Loss Compound to Third Party

May 5, 2014

Dr. John Bonfiglio, CEO of Oragenics Inc (OGEN), says the company decided to license its LPT3-04 weight-loss compound to an outside third party.

“The Phase II trial did show a significant weight loss in some patients,” Bonfiglio says. “But given the focus of the company on ethical therapeutic drugs, at this point in time, we didn’t have the bandwidth or the resources to move that forward, so we have licensed that out.”

FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.

Bonfiglio says that when he joined Oragenics in 2011, there were many different technologies under consideration. Bonfiglio says his strategy is to focus on antibiotics, which is the area where he believes the company can make the most progress.

“Because with our relationship with Intrexon, we not only have the lead compound that was discovered by us, but we have been able to generate a whole pipeline of new analogs of this lead compound, MU1140, that we believe have the possibility of being extremely helpful in the fight against resistant bacteria,” Bonfiglio says. “That’s one area where we think the value of the company would greatly be enhanced by the continued development of those products.”